How to Save London: The Readout With Julian Harris

Indivior is a pharma company specializing in treating various types of addiction. If you’re in Britain, you may not have even heard of it. After all, more than 80% of its sales come from the US, its CEO is American, its headquarters are in Virginia and the authorities in Washington DC are a major customer.

Little surprise, then, that Indivior is set to become the latest British-listed company to swap the Square Mile for Wall Street, with the FTSE 250 business confirming this morning that it will consult shareholders over a plan to move its primary listing this summer.